Home › NDC Lookup › RxCUI directory › RxCUI 763453

Rilonacept 220 MG Injection — RxCUI 763453

RxNorm drug concept · Semantic clinical drug
RxCUI 763453 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI763453
Official nameRilonacept 220 MG Injection
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped1
Package NDCs mapped2
Reported Medicaid activity (SDUD)2,050 prescriptions · 24 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Rilonacept Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Arcalyst is neither a steroid nor a traditional immunotherapy. It's a targeted biologic — a protein designed to block two specific inflammatory signals called IL-1α and IL-1β that...
  • What exactly is Arcalyst treating — is it a steroid or immunotherapy?
  • Arcalyst comes as a powder that you mix with sterile water before injecting it just under the skin — a subcutaneous injection, similar to an insulin shot. The most common complaint...
  • How do I give myself the injection, and does it hurt?
📖 Read our full Rilonacept Injection guide →

🕸️ Concept Web — How Rilonacept 220 MG Injection Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Rilonacept 220 MG Injection RxCUI 763453

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Rilonacept 763450
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Arcalyst 763454
  3. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Rilonacept Injection 1724259
    • Rilonacept Injectable Product 1157438
    • Rilonacept Injection [Arcalyst] 1724262
    • Arcalyst Injectable Product 1170102
    • Injection 1649574
    • Injectable Product 1151126
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Rilonacept 220 MG SCDC · 1724258
  • Rilonacept Injection SCDF · 1724259
  • Rilonacept Injectable Product SCDG · 1157438

Brand-Name Concepts

  • Rilonacept 220 MG Injection [Arcalyst] SBD · 763457
  • Rilonacept 220 MG [Arcalyst] SBDC · 1724261
  • Rilonacept Injection [Arcalyst] SBDF · 1724262
  • Arcalyst Injectable Product SBDG · 1170102
  • Arcalyst BN · 763454

📦 FDA Products & Package NDCs

1 product · 2 package NDCs
2 package NDCs map to RxCUI 763453 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
73604-0914-01 1 VIAL, SINGLE-USE in 1 CARTON (73604-914-01) / 2 mL in 1 V... Arcalyst Kiniksa Pharmaceuticals (UK), Ltd. 2021-06-18
73604-0914-04 4 VIAL, SINGLE-USE in 1 CARTON (73604-914-04) / 2 mL in 1 V... Arcalyst Kiniksa Pharmaceuticals (UK), Ltd. 2008-03-24
Observed labelers: Kiniksa Pharmaceuticals (UK), Ltd. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.